Latest Articles
Cumulative Abdominal Obesity Raises Young Women’s Cancer Risk - BIOENGINEER.ORG
Cumulative Abdominal Obesity Raises Young Women’s Cancer Risk BIOENGINEER.ORG
Published: Aug. 22, 2025, 7:26 p.m.
Cumulative abdominal obesity exposure and progressive risk of endometrial cancer in young women: a nationwide cohort study - Nature
Cumulative abdominal obesity exposure and progressive risk of endometrial cancer in young women: a nationwide cohort study Nature
Published: Aug. 22, 2025, 6:50 p.m.
BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer - TipRanks
BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer TipRanks
Published: Aug. 22, 2025, 4:17 p.m.
NIH Grants Funding to Investigate Socio-Genomic Influences on Local Endometrial Cancer Survival Rates - BIOENGINEER.ORG
NIH Grants Funding to Investigate Socio-Genomic Influences on Local Endometrial Cancer Survival Rates BIOENGINEER.ORG
Published: Aug. 22, 2025, 3:41 a.m.
NIH award to explore socio-genomic factors of local endometrial cancer survival rates - EurekAlert!
NIH award to explore socio-genomic factors of local endometrial cancer survival rates EurekAlert!
Published: Aug. 21, 2025, 4:11 p.m.
Ozempic Linked to Reduced Cancer Risk - Newsweek
Ozempic Linked to Reduced Cancer Risk Newsweek
Published: Aug. 21, 2025, 3 p.m.
Wayne State researcher receives NIH award to explore socio-genomic factors of local endometrial cancer survival rates - Today@Wayne
Wayne State researcher receives NIH award to explore socio-genomic factors of local endometrial cancer survival rates Today@Wayne
Published: Aug. 21, 2025, 1:46 p.m.
NIH Award to Explore Socio-Genomic Factors of Local Endometrial Cancer Survival Rates | Newswise - Newswise
NIH Award to Explore Socio-Genomic Factors of Local Endometrial Cancer Survival Rates | Newswise Newswise
Published: Aug. 21, 2025, 1:40 p.m.
BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer - TipRanks
BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer TipRanks
Published: Aug. 20, 2025, 4:07 p.m.
AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? - TipRanks
AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? TipRanks
Published: Aug. 20, 2025, 4:07 p.m.
Link copied to clipboard!